AbbVie Inc (ABBV)vsEnanta Pharmaceuticals Inc (ENTA)
ABBV
AbbVie Inc
$227.23
-2.70%
HEALTHCARE · Cap: $380.57B
ENTA
Enanta Pharmaceuticals Inc
$11.28
-3.84%
HEALTHCARE · Cap: $328.00M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 90662% more annual revenue ($62.82B vs $69.21M). ABBV leads profitability with a 5.8% profit margin vs -89.6%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ENTA
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+41.4%
Fair Value
$24.33
Current Price
$11.28
$13.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
15.0% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ENTA
The strongest argument for ENTA centers on Price/Book, Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while ENTA is a turnaround play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.99 — expect wider price swings.
ENTA is growing revenue faster at 15.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. ENTA offers better value entry with a 41.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?